CR-1-31-B

News alerts, weekly reports and conference planners

Company:

McGill University

Drug class:

eIF4A1 inhibitor

Related drugs:

KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	palbociclib + CR-1-31-B Sensitive: D – Preclinical palbociclib + CR-1-31-B Sensitive : D	palbociclib + CR-1-31-B Sensitive: D – Preclinical palbociclib + CR-1-31-B Sensitive : D
ER positive	Estrogen Receptor Positive Breast Cancer	ER positive	Estrogen Receptor Positive Breast Cancer	palbociclib + CR-1-31-B Sensitive: D – Preclinical palbociclib + CR-1-31-B Sensitive : D	palbociclib + CR-1-31-B Sensitive: D – Preclinical palbociclib + CR-1-31-B Sensitive : D

Associations
(2)